[go: up one dir, main page]

CA2067221A1 - Derive pyrimidine a cycles condenses, procede pour sa preparation et preparation pharmaceutique en contenant comme ingredient actif - Google Patents

Derive pyrimidine a cycles condenses, procede pour sa preparation et preparation pharmaceutique en contenant comme ingredient actif

Info

Publication number
CA2067221A1
CA2067221A1 CA2067221A CA2067221A CA2067221A1 CA 2067221 A1 CA2067221 A1 CA 2067221A1 CA 2067221 A CA2067221 A CA 2067221A CA 2067221 A CA2067221 A CA 2067221A CA 2067221 A1 CA2067221 A1 CA 2067221A1
Authority
CA
Canada
Prior art keywords
same
preparation
active ingredient
pharmaceutical preparation
pyrimidine derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2067221A
Other languages
English (en)
Other versions
CA2067221C (fr
Inventor
Yasuji Sakuma
Masaichi Hasegawa
Kenichiro Kataoka
Kenji Hoshina
Noboru Yamazaki
Takashi Kadota
Hisao Yamaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2067221A1 publication Critical patent/CA2067221A1/fr
Application granted granted Critical
Publication of CA2067221C publication Critical patent/CA2067221C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002067221A 1989-10-11 1990-10-11 Derive pyrimidine a cycles condenses, procede pour sa preparation et preparation pharmaceutique en contenant comme ingredient actif Expired - Fee Related CA2067221C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26476389 1989-10-11
JP1-264763 1989-10-11

Publications (2)

Publication Number Publication Date
CA2067221A1 true CA2067221A1 (fr) 1991-04-12
CA2067221C CA2067221C (fr) 1997-04-15

Family

ID=17407851

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002067221A Expired - Fee Related CA2067221C (fr) 1989-10-11 1990-10-11 Derive pyrimidine a cycles condenses, procede pour sa preparation et preparation pharmaceutique en contenant comme ingredient actif

Country Status (11)

Country Link
US (1) US5378700A (fr)
EP (1) EP0495982B1 (fr)
JP (1) JP2541702B2 (fr)
KR (1) KR0155955B1 (fr)
AT (1) ATE139232T1 (fr)
AU (1) AU645504B2 (fr)
CA (1) CA2067221C (fr)
DE (1) DE69027440T2 (fr)
DK (1) DK0495982T3 (fr)
ES (1) ES2087916T3 (fr)
WO (1) WO1991005784A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0514540B1 (fr) * 1989-09-19 1996-07-17 Teijin Limited DERIVE DE PYRROLO 2,3-d]PYRIMIDINE, SON PROCEDE DE PREPARATION, ET PREPARATION PHARMACEUTIQUE COMPRENANT LE DERIVE COMME INGREDIENT ACTIF
US5254716A (en) * 1992-10-15 1993-10-19 Eli Lilly And Company Intermediates, and processes thereto, for the preparation of 5,6-dihydropyrrolo[2,3-d]pyrimidines
FR2699176B1 (fr) * 1992-12-11 1995-03-03 Adir Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant.
WO1995033752A1 (fr) * 1994-06-09 1995-12-14 Smithkline Beecham Corporation Antagonistes du recepteur de l'endotheline
US6020492A (en) 1995-05-12 2000-02-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
JP3290666B2 (ja) * 1995-06-07 2002-06-10 ファイザー・インコーポレーテッド 複素環式の縮合環ピリミジン誘導体
US6395733B1 (en) 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
WO1998000426A1 (fr) * 1996-06-28 1998-01-08 The Trustees Of Princeton University DERIVES DE 5,6,7,8-TETRAHYDROPYRIMIDO[4,5-b]AZEPINE
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
WO1999011643A1 (fr) * 1997-09-02 1999-03-11 Du Pont Pharmaceuticals Company Pyridines a cycle fusionne et a substitution heterocyclyle, antagonistes du facteur de liberation de la cortitropine (crf), utiles dans le traitement des troubles lies au snc et au stress
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
JP2002510686A (ja) 1998-04-02 2002-04-09 ニューロゲン コーポレイション アミノアルキルで置換された５，６，７，８−テトラヒドロ−９Ｈ−ピリジノ［２，３−ｂ］インドール及び５，６，７，８−テトラヒドロ−９Ｈピリミジノ［４，５−Ｂ］インドール誘導体：ＣＲＦ１特異的配位子
AU4556999A (en) 1998-06-09 1999-12-30 Neurogen Corporation Pyrido[2,3-b]indolizine derivatives and aza analogues thereof; crf1 specific ligands
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
US20070021429A1 (en) * 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
WO2008018426A1 (fr) 2006-08-08 2008-02-14 Chugai Seiyaku Kabushiki Kaisha Dérivé de pyrimidine comme inhibiteur de la PI3K et son utilisation
WO2008157208A2 (fr) 2007-06-13 2008-12-24 Incyte Corporation Sels de l'inhibiteur (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile de la janus kinase
CN101918079A (zh) * 2008-01-22 2010-12-15 默克专利有限公司 蛋白激酶抑制剂及其用途
CL2009000241A1 (es) * 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
WO2009107767A1 (fr) * 2008-02-29 2009-09-03 大日本住友製薬株式会社 Nouveau dérivé de pyrimidine bicyclique qui présente une activité antagoniste sur le récepteur h4
DK2432472T3 (da) 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PH12015502575A1 (en) * 2010-03-10 2017-04-24 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP3087972A1 (fr) 2010-05-21 2016-11-02 Incyte Holdings Corporation Formulation topique pour un inhibiteur jak
CA2818545C (fr) 2010-11-19 2019-04-16 Incyte Corporation Pyrrolopyridines et pyrrolopyrimidines a substitution heterocyclique utilisees en tant qu'inhibiteurs des jak
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
EP2646423A4 (fr) 2010-11-29 2014-04-30 Galleon Pharmaceuticals Inc Nouveaux composés comme stimulants respiratoires pour le traitement de troubles ou de maladies de contrôle de la respiration
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
EP3949953A1 (fr) 2012-11-15 2022-02-09 Incyte Holdings Corporation Formes posologiques à libération prolongée de ruxolitinibe
BR112015021458B1 (pt) 2013-03-06 2022-06-07 Incyte Holdings Corporation "processos e intermediários para preparar {1-{1-[3-flúor2-(trifluormetil)isonicotinoil] piperidin-4-il}-3-[4-(7hpirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrila, útil no tratamento de doenças relacionadas com a atividade de janus quinases
WO2015021153A1 (fr) 2013-08-07 2015-02-12 Incyte Corporation Formes galéniques à libération prolongée pour un inhibiteur jak1
WO2015184305A1 (fr) 2014-05-30 2015-12-03 Incyte Corporation Traitement de la leucémie neutrophile chronique (cnl) et de la leucémie myéloïde chronique atypique (acml) par des inhibiteurs de jak1
JP7562256B2 (ja) * 2016-08-15 2024-10-07 パデュー リサーチ ファウンデイション ４位置換アミノイソキノリン誘導体
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
DK3746429T3 (da) 2018-01-30 2022-05-02 Incyte Corp Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on)
CN112423759A (zh) 2018-03-30 2021-02-26 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3631045A (en) * 1969-11-04 1971-12-28 American Home Prod 4 5-diamino-7h-pyrrolo(2 3-d)pyrimidine derivatives
EP0514540B1 (fr) * 1989-09-19 1996-07-17 Teijin Limited DERIVE DE PYRROLO 2,3-d]PYRIMIDINE, SON PROCEDE DE PREPARATION, ET PREPARATION PHARMACEUTIQUE COMPRENANT LE DERIVE COMME INGREDIENT ACTIF

Also Published As

Publication number Publication date
DE69027440D1 (de) 1996-07-18
US5378700A (en) 1995-01-03
EP0495982B1 (fr) 1996-06-12
DK0495982T3 (da) 1996-07-01
ATE139232T1 (de) 1996-06-15
EP0495982A1 (fr) 1992-07-29
AU645504B2 (en) 1994-01-20
WO1991005784A1 (fr) 1991-05-02
CA2067221C (fr) 1997-04-15
ES2087916T3 (es) 1996-08-01
DE69027440T2 (de) 1997-02-06
KR0155955B1 (ko) 1998-11-16
EP0495982A4 (en) 1994-07-20
JP2541702B2 (ja) 1996-10-09
AU6522090A (en) 1991-05-16

Similar Documents

Publication Publication Date Title
CA2067221A1 (fr) Derive pyrimidine a cycles condenses, procede pour sa preparation et preparation pharmaceutique en contenant comme ingredient actif
CA2369070A1 (fr) Derives de 1,4-benzothiazepin-1,1-dioxyde substitues par des residus de sucre, leur procede de production, des medicaments contenant ces composes et leur utilisation
EP0382526A3 (fr) 1,3-oxathiolanes substitués doués de propriétés antivirales
EP0664289A3 (fr) Isoquinoléines
EP1304322A3 (fr) Composé d'acide carboxylique et son utilisation
CA2381097A1 (fr) Derives d'arylmethyl-carbonylamino-thiazole utilisation de ceux-ci comme agents antitumoraux
AU658619B2 (en) Benzopyranones, methods of manufacture and use thereof
CA2044515A1 (fr) Derives d'amides cycliques
AU4500793A (en) Derivatives in the vitamin d series modified at the 20 position, a method of preparing such derivatives, intermediates used in this method, pharmaceutical preparations containing the derivatives and their use in the preparation of drugs
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
DE3752384D1 (de) Pteridinderivat enthaltende pharmazeutische Zusammensetzung
EP0747383A3 (fr) Sels de polyamine d'acide clavulanique
CA2040982A1 (fr) Derives n-(3-fluoro-2-phosphonylmethoxypropyle) des bases heterocycliques purine et pyrimidine, methode pour leur production et utilisation comme principes actifs de medicaments
CA2187409A1 (fr) Sels d'acide tetrahydrofolique, cristallises, stables
CA2234319A1 (fr) Derives de substitution fluores d'adamantine
KR910015562A (ko) 뇌부전 질환치료용 약제, 신규 2-(1-피페라지닐)-4-페닐시클로알카노 피리미딘 유도체, 및 그의 제법
EP0144235A3 (fr) N6-(1-et 2-benzocycloalkyl)adénosines, compositions pharmaceutiques les contenant et leur procédés de préparation
DE68915341T2 (de) Expektoranz, das ein Hydroxy-alkyl-cystein-Derivat enthält.
WO1993014767A3 (fr) Preparation pharmaceutique a base de rhamnolipides utilisee pour traiter les maladies dermatologiques, par exemple, les infections du virus du papillome
EP1069125A3 (fr) Dérivés carbamates de 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones et d'analogues de l'acide 1-amino-1-cyclopropane carboxylique, procédé pour leur préparation et leur application comme médicaments
EP0205334A3 (fr) Dérivés de benzazépine
CA2300289A1 (fr) Composition pharmaceutique active dans la reduction de production de proteine mcp-1
FR2407928A1 (fr) Derives de quinazoline utiles comme medicaments antihypertenseurs et procede de leur preparation
HUT50334A (en) Process for producing arylpiperazinyl-alkilenephenyl-p-heterocycluc compounds, pharmaceutically acceptable acid addition salts thereof and pharmaceutical compositions comprising the compounds as active ingredient
EP0354568A3 (fr) Dérivés du catéchol

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20041012